PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials

Summary This study evaluated the expression of PD‐L1 in immunotherapy‐naïve metastatic melanoma patients to determine longitudinal intrapatient concordance and correlate PD‐L1 status with clinicopathologic characteristics and outcome. PD‐L1 expression was assessed by immunohistochemistry in 58 patie...

Full description

Saved in:
Bibliographic Details
Published in:Pigment cell and melanoma research 2015-05, Vol.28 (3), p.245-253
Main Authors: Madore, Jason, Vilain, Ricardo E., Menzies, Alexander M., Kakavand, Hojabr, Wilmott, James S., Hyman, Jessica, Yearley, Jennifer H., Kefford, Richard F., Thompson, John F., Long, Georgina V., Hersey, Peter, Scolyer, Richard A.
Format: Article
Language:English
Subjects:
B7-H1 Antigen - metabolism
biomarker
Clinical Trials as Topic
diagnosis
Female
Genetic Heterogeneity
Heterogeneity
Humans
Immunohistochemistry
Immunotherapy
Lymphocytes, Tumor-Infiltrating - immunology
Male
Medical research
Melanoma
Melanoma - immunology
Melanoma - metabolism
Melanoma - pathology
Metastasis
Middle Aged
Neoplasm Grading
Neoplasm Metastasis
pathology
PD-1
PD-L1
Prognosis
Skin Neoplasms - immunology
Skin Neoplasms - metabolism
Skin Neoplasms - pathology
Survival Analysis
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!